What is Iambic?
Founded in 2020 and based in San Diego, Iambic is at the forefront of applying artificial intelligence to drug discovery and development. The company has built a robust platform that has demonstrated the ability to rapidly advance new drug candidates into human clinical trials across diverse target classes and mechanisms of action. Iambic's core strength lies in its interdisciplinary team, which combines expertise in AI with extensive experience in drug development, positioning the company to address urgent unmet patient needs with innovative therapeutic solutions.
How much funding has Iambic raised?
Iambic has raised a total of $277.8M across 3 funding rounds:
Series B
$150M
Other Financing Round
$100M
Private Equity
$27.8M
Series B (2024): $150M with participation from Mubadala Capital, Coatue, Exor Ventures, Abingworth, and Ascenta Finance
Other Financing Round (2025): $100M led by Alumni Ventures, Catalio Capital Management, Ascenta Capital, and Abingworth
Private Equity (2026): $27.8M, investors not publicly disclosed
Key Investors in Iambic
Alumni Ventures
Alumni Ventures is an investment firm that manages venture capital funds for top colleges and universities, focusing on providing a structured approach to venture investing.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare and biomedical technology companies across private, public, and credit markets.
Ascenta Capital
Ascenta Capital is dedicated to helping innovative biotech companies transition from scientific foundations to clinical development, focusing on patient-centered innovations.
What's next for Iambic?
With the recent influx of major strategic investment, Iambic is poised for significant expansion and acceleration of its development programs. The substantial capital infusion is expected to fuel the advancement of its internal pipeline and support potential partnerships, enabling the company to move more drug candidates through clinical trials. This funding round, characterized as enterprise-level, suggests Iambic is moving into a scaling phase, focusing on robust clinical validation and potentially preparing for later-stage development or commercialization strategies. The company's ability to consistently deliver drug candidates to trials at an unprecedented speed will be critical in leveraging this investment for long-term growth and impact in the life sciences sector.
See full Iambic company page
